Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Efruxifermin in Non-Cirrhotic NASH/MASH and Fibrosis
NCT06215716Phase 3Recruiting
- Sponsor
- Akero Therapeutics
- Start
- Dec 2023
- Primary completion
- Feb 2033
- Modality
- Fc-Fusion Proteins
- Countries
- 18
01
Overview
A Phase 3 trial of efruxifermin in Nonalcoholic steatohepatitis (NASH), sponsored by Akero Therapeutics. Started Dec 2023; status: recruiting.
02
Drugs
efruxifermin
03
Conditions
Nonalcoholic steatohepatitis (NASH)
Beyond the preview
Go deeper on NCT06215716.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06215716.